Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Gomoll

Repeat Administration of Triamcinolone Acetonide Extended-Release Affords Consistent, Clinically Relevant Improvements in Pain: Results From a Phase 3B, Single-Arm, Open-Label Study

Osteoarthritis and Cartilage

Sports Medicine

Rheumatology

Orthopedics

Biomedical Engineering

2019

English

Related publications

Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results From Three Nonclinical Toxicity Studies in Dogs

Rheumatology and Therapy

2018

English

Safety and Systemic Exposure of Triamcinolone Acetonide Following Intra-Articular Injection of Triamcinolone Acetonide Extended-Release or Standard Triamcinolone in Patients With Hip Osteoarthritis

Osteoarthritis and Cartilage

Sports Medicine

Rheumatology

Orthopedics

Biomedical Engineering

2019

English

Expanding the Potential of Nonoperative Therapies in Advanced Knee Osteoarthritis: Treatment Response to Repeat Administration Triamcinolone Acetonide Extended-Release Is Similar Across Kellgren-Lawrence Grades 2-4

Orthopaedic Journal of Sports Medicine

Orthopedics

Sports Medicine

2019

English

Improvement in Social and Cognitive Functioning Associated With Paliperidone Extended-Release Treatment in Patients With Schizophrenia: A 24-Week, Single Arm, Open-Label Study

Neuropsychiatric Disease and Treatment

2016

English

Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study

Asia-Pacific Journal of Clinical Oncology

Medicine

Oncology

2017

English

Triamcinolone Acetonide

Reactions

1980

English

Once-Weekly Ofatumumab in Untreated or Relapsed Waldenström's Macroglobulinaemia: An Open-Label, Single-Arm, Phase 2 Study

The Lancet Haematology

Hematology

2017

English

Rescue Analgesic Medication Use by Patients Treated With Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials

English

Efficacy and Safety of Privigen®in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Results of a Prospective, Single-Arm, Open-Label Phase III Study (The PRIMA Study)

Journal of the Peripheral Nervous System

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Gomoll

Repeat Administration of Triamcinolone Acetonide Extended-Release Affords Consistent, Clinically Relevant Improvements in Pain: Results From a Phase 3B, Single-Arm, Open-Label Study

Related publications

Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results From Three Nonclinical Toxicity Studies in Dogs

Safety and Systemic Exposure of Triamcinolone Acetonide Following Intra-Articular Injection of Triamcinolone Acetonide Extended-Release or Standard Triamcinolone in Patients With Hip Osteoarthritis

Expanding the Potential of Nonoperative Therapies in Advanced Knee Osteoarthritis: Treatment Response to Repeat Administration Triamcinolone Acetonide Extended-Release Is Similar Across Kellgren-Lawrence Grades 2-4

Improvement in Social and Cognitive Functioning Associated With Paliperidone Extended-Release Treatment in Patients With Schizophrenia: A 24-Week, Single Arm, Open-Label Study

Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study

Triamcinolone Acetonide

Once-Weekly Ofatumumab in Untreated or Relapsed Waldenström's Macroglobulinaemia: An Open-Label, Single-Arm, Phase 2 Study

Rescue Analgesic Medication Use by Patients Treated With Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials

Efficacy and Safety of Privigen®in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Results of a Prospective, Single-Arm, Open-Label Phase III Study (The PRIMA Study)